{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:30Z","timestamp":1753891890530,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>A 20-year-old male patient with a history of celiac disease came to medical attention after developing profound fatigue and pancytopenia. Evaluation demonstrated pan-hypogammaglobulinemia. There was no history of significant clinical infections. Bone marrow biopsy confirmed hypocellular marrow consistent with aplastic anemia. Oncologic and hematologic evaluations were unremarkable for iron deficiency, paroxysmal nocturnal hemoglobinuria, myelodysplastic syndromes, T-cell clonality, and leukemia. A next generation genetic sequencing immunodeficiency panel revealed a heterozygous variant of uncertain significance in <jats:italic>CTLA4<\/jats:italic> c.385T &amp;gt;A, p.Cys129Ser (C129S). Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an inhibitory receptor important in maintaining immunologic homeostasis. To determine the functional significance of the C129S variant, additional testing was pursued to assess for diminished protein expression, as described in other pathogenic <jats:italic>CTLA4<\/jats:italic> variants. The results demonstrated severely impaired CTLA-4 expression and CD80 transendocytosis, consistent with other variants causing CTLA-4 haploinsufficiency. He was initially treated with IVIG and cyclosporine, and became transfusion independent for few months, but relapsed. Treatment with CTLA-4<jats:italic>-<\/jats:italic>Ig fusion protein (abatacept) was considered, however the patient opted for definitive therapy through reduced-intensity haploidentical hematopoietic stem cell transplant, which was curative.<\/jats:p>","DOI":"10.3389\/fped.2024.1434076","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T14:46:25Z","timestamp":1723819585000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Aplastic anemia related to a novel CTLA4 variant"],"prefix":"10.3389","volume":"12","author":[{"given":"Geoffrey","family":"Hall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet G.","family":"Markle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Maiarana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Sleasman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Lederman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine E.","family":"Azar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talal","family":"Mousallem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"eabb1662","DOI":"10.1126\/sciimmunol.abb1662","article-title":"Human inborn errors of immunity: an expanding universe","volume":"5","author":"Notarangelo","year":"2020","journal-title":"Sci Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/ACI.0000000000000689","article-title":"Primary immune regulatory disorders: a growing universe of immune dysregulation","volume":"20","author":"Chan","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"volume-title":"Cellular and Molecular Immunology","year":"2022","author":"Abbas","key":"B3"},{"key":"B4","first-page":"7","volume-title":"Molecular and Cellular Functions of CTLA-4","author":"Van Coillie","year":"2020"},{"key":"B5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"B6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9296","DOI":"10.1073\/pnas.94.17.9296","article-title":"Thymocyte development is normal in CTLA-4-deficient mice","volume":"94","author":"Chambers","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1074-7613(00)80406-9","article-title":"Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells","volume":"7","author":"Chambers","year":"1997","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/aje\/kwi165","article-title":"CTLA-4 gene polymorphisms and susceptibility to type 1 diabetes mellitus: a HuGE review and meta-analysis","volume":"162","author":"Kavvoura","year":"2005","journal-title":"Am J Epidemiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0165-5728(99)00072-7","article-title":"The CTLA-4 gene is associated with multiple sclerosis","volume":"97","author":"Ligers","year":"1999","journal-title":"J Neuroimmunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12020-016-1096-1","article-title":"CD28\/CTLA-4\/ICOS haplotypes confers susceptibility to Graves\u2019 disease and modulates clinical phenotype of disease","volume":"55","author":"Pawlak-Adamska","year":"2017","journal-title":"Endocrine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.3389\/fimmu.2018.02012","article-title":"Increased risk for malignancies in 131 affected CTLA4 mutation carriers","volume":"9","author":"Egg","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.annepidem.2010.05.013","article-title":"Hemochromatosis genotypes and risk of iron overload\u2013a meta-analysis","volume":"21","author":"Neghina","year":"2011","journal-title":"Ann Epidemiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0016-5085(02)80116-0","article-title":"A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation","volume":"122","author":"Gochee","year":"2002","journal-title":"Gastroenterology"},{"volume-title":"DRI, Dietary Reference Intakes: The Essential Guide to Nutrient Requirements","year":"2006","author":"Otten","key":"B16"},{"key":"B17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.imbio.2014.02.010","article-title":"Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of south Florida","volume":"219","author":"Valiathan","year":"2014","journal-title":"Immunobiology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/ejh.12299","article-title":"Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes","volume":"92","author":"DeZern","year":"2014","journal-title":"Eur J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.4049\/jimmunol.1401876","article-title":"A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells","volume":"194","author":"Hou","year":"2015","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e13994","DOI":"10.1111\/pai.13994","article-title":"Deep immunophenotyping shows altered immune cell subsets in CTLA-4 haploinsufficiency","volume":"34","author":"Maiarana","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e14077","DOI":"10.1111\/pai.14077","article-title":"Expanding the molecular and phenotypic spectrum of CTLA-4 insufficiency","volume":"35","author":"Duke","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1182\/blood-2018-99-120185","article-title":"Management of cytopenias in CTLA4 haploinsufficiency using abatacept and sirolimus","volume":"132","author":"Uzel","year":"2018","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaci.2015.08.036","article-title":"Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4","volume":"137","author":"Lee","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s10875-018-0511-1","article-title":"Treatment of intracerebral lesions with abatacept in a CTLA4-haploinsufficient patient","volume":"38","author":"van Leeuwen","year":"2018","journal-title":"J Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1182\/blood.2023020435","article-title":"Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia","volume":"141","author":"DeZern","year":"2023","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.jaci.2019.12.896","article-title":"Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score","volume":"145","author":"Tesch","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.aaa1663","article-title":"AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science"},{"year":"2024","article-title":"ORENCIA (Abatacept)","key":"B29"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1434076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T14:46:33Z","timestamp":1723819593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1434076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":29,"alternative-id":["10.3389\/fped.2024.1434076"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1434076","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"article-number":"1434076"}}